Alpha TAU Medical raises $26 million funding as it moves to Jerusalem
Alpha Tau Medical, the developer of breakthrough alpha-radiation cancer therapy Alpha DaRT, finished in June the closing of a Series B equity financing of $26
FDA Accepts Atox Bio’s Reltecimod to Treat Suspected Organ Dysfunction/Failure re “Flesh-Eating Disease”
The U.S. Food and Drug Administration (FDA) has accepted to Atox Bio’s filing of the New Drug Application (NDA) for Reltecimod with a Prescription Drug
Ascento Medical Gives New Hope for Alzheimer’s and Dementia Patients
Ascento Medical is a company in the field of Dementia and Alzheimer’s treatment & prevention, using Artificial Intelligence and Machine Learning to optimize a proven
KAHR Announces First Patient Dosed in DSP107 Treatment of Solid Tumors Phase 1/2 Clinical Trial
Jerusalem based KAHR MEDICAL, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, started treating the first patient in its Phase 1/2 clinical trial (NCT04440735)
Raziel Closes Market License Agreement for RZL 012 with Fosun Pharma
Raziel Therapeutics, a Pharmaceutical company, is developing a novel synthetic small molecule (NCE) for aesthetics and fat disorders next-generation novel prescription products. Raziel Therapeutics licensed
Oramed to Start Pivotal Phase 3 Oral Insulin Studies
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company is about to start their Phase 3 Studies for their oral insulin candidate
Omnix Medical Raises $8.5 million for its Novel Drug Targeting AMR Bacteria
Omnix Medical just raised an additional $8.5 million to bring its promising AMR (antimicrobial resistance) drug, OMN6, for the treatment of hospital-acquired infections, to clinical
Promising Results in Immunity Pharma’s Interim Phase 1/2a IPL344 in ALS Study
The new treatment being developed by Immunity Pharma may give ALS (Lou Gehrig’s Disease) patients hope. ALS is an “orphan disease” – one that affects
Mapi Pharma In Talks To Produce Covid-19 Vaccine in Jerusalem
Israeli drug development company Mapi Pharma announced today that it will dedicate capacity at its manufacturing facility in Jerusalem’s Har Hotzvim industrial park to produce
